Metabolomics Study on Postoperative Intensive Care Acquired Muscle Weakness
NCT03810768
Critical Care, Critical Illness
Vienna, State of Vienna, Austria
View Trial DetailsNCT Number: NCT06419699
Intensive care unit (ICU) acquired weakness is a common complication associated with long-term physical impairments in survivors of a critical illness. The Chelsea Critical Care Physical Assessment tool (CPAx) is a valid and reliable instrument for physical function and activity in critically ill patients at risk for muscle weakness. However, its ability to measure change over time (responsiveness) and the minimal clinically important difference (MCID) have not yet been rigorously investigated. This multi-centre, mixed-methods, longitudinal cohort study therefore aims to establish responsiveness and the MCID of the CPAx in the target population from ICU baseline to ICU and hospital discharge. The study uses routine data from standard physiotherapy sessions like mobility, function and activity with no additional burden for critically ill adults. The investigators expect the CPAx to be responsive allowing its use as a primary outcome in future effectiveness trials for the treatment of ICU-acquired weakness using the newly established MCID for sample size calculation. A high quality, rigorously tested measurement tool for physical function and activity in the ICU should benefit researchers, clinicians and patients.
This study is active but is not currently recruiting participants.
18 year and older
All sexes
Observational
Monash Health, Clayton, Australia
The use of invasive life support in critically ill patients clearly saves lives but carries substantial risks, including intensive care unit (ICU) acquired weakness and long-term disability. The investigators urgently need a valid, reliable, and responsive measurement tool for this population to use in clinical practice and trials. The Chelsea Critical Care Physical Assessment tool (CPAx) is a promising measurement instrument to measure change in critically ill patients' physical function and activity. After several studies have confirmed its validity and excellent reliability, it is time to confirm responsiveness and to establish the MCID in a large, international sample of the target population. This multi-centre, mixed-methods, longitudinal cohort study will include critically ill, mechanically ventilated (>72h) adults at risk for muscle weakness and collect their mobility, physical function and activity with the CPAx and other relevant measures at ICU baseline, to ICU and hospital discharge. Responsiveness will be determined by the ability of the CPAx to identify change according to a prespecified anchor (criterion validity) and by testing prospective hypotheses about the expected magnitude of change between the CPAx and other relevant measures (construct validity). The MCID will be established with anchor- and distribution-based methods, whereby a seven-point global rating of change scale obtained from treating ICU physiotherapists will serve as anchor to distinguish improved from unchanged patients.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Assessed at ICU discharge (within 24 hours before or after ICU discharge)
CPAx change score for ICU period (ICU baseline to ICU discharge); CPAx ranges from 0 (worst score) to 50 (best score)
Time frame: Assessed at hospital discharge (last value before discharge)
CPAx change score for hospital period (ICU to hospital discharge); CPAx ranges from 0 (worst score) to 50 (best score)
Time frame: ICU and hospital discharge (change for ICU and hospital period)
Seven-point global rating of change scale (GRC): (1) very much improved; (2) much improved; (3) little improved; (4) no change; (5) little deterioration; (6) much deterioration; (7) very much deterioration for 'physical function and activity' (rated by treating physiotherapist)
Time frame: ICU baseline (within 72-144h after ICU admission), ICU and hospital discharge
To evaluate mobility level, the score ranges from 0 (worst) to 10 (best)
Time frame: ICU baseline (within 72-144h after ICU admission), ICU and hospital discharge
To assess muscle strength, the minimal score is 0 (worst), the maximal score 60 (best), ICUAW is defined as <48 points
Time frame: ICU baseline (within 72-144h after ICU admission), ICU and hospital discharge
To assess the level of sedation and/or cooperation, score ranges from -5 (unarousable) to +4 (combative)
Time frame: ICU baseline (within 72-144h after ICU admission), ICU and hospital discharge
To determine assistance in functional tasks, the score ranges from 0 (worst) to 36 (best)
Time frame: ICU and hospital discharge
Categorical variable (death, external/internal hospital ward, external ICU/hospital, rehabilitation, home, other) to assess the predictive validity of the CPAx score
Insel Gruppe AG, University Hospital Bern
Other
Responsiveness and the Minimal Clinically Important Difference of the Chelsea Critical Care Physical Assessment Tool (CPAx) in Critically Ill, Mechanically Ventilated Adults
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03810768
Critical Care, Critical Illness
Vienna, State of Vienna, Austria
View Trial DetailsNCT03819959
Critical Care, Critical Illness
Munich, Bavaria, Germany
View Trial DetailsNCT03115840
Behavior, Cognition Disorders
Columbus, Ohio, United States
View Trial DetailsNCT06064292
Aging, Behavior
Salamanca, Spain
View Trial Details